Int. J. Mol. Sci. 2013, 14(4), 7016-7031; doi:10.3390/ijms14047016

Trends in Nanopharmaceutical Patents

1 National Institute of Industrial Property (Brazil), Mayrink Veiga, n° 9 Centro, Rio de Janeiro, Brazil 2 Federal University of Rio de Janeiro, Postgraduate Program on Technology of Chemical & Biochemical Processes, Av. Horácio Macedo, 2030, Centro de Tecnologia, Bloco I sala I-222, Cidade universitária, Rio de Janeiro, Brazil 3 Oswaldo Cruz Foundation, Institute of Scientific and Technological Communication and Information in Health, Av. Brasil, number 4.365 - Pavilhão Haity Moussatché - Manguinhos, Rio de Janeiro 21.045-360, Brazil These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 28 December 2012; in revised form: 14 March 2013 / Accepted: 15 March 2013 / Published: 27 March 2013
(This article belongs to the Special Issue Bioactive Nanoparticles 2012)
PDF Full-text Download PDF Full-Text [219 KB, Updated Version, uploaded 28 March 2013 17:47 CET]
The original version is still available [219 KB, uploaded 27 March 2013 11:05 CET]
Abstract: Investment in nanotechnology is now a given constant by governments, research centers and companies in both more developed countries and emerging markets. Due to their characteristics, such as high stability, ability to enable antigen identification on specific cells in the human body and controlling the release of drugs and, therefore, improving therapies, nanoparticles have been the subject of research and patent applications in the pharmaceutical field. According to the Organization for Economic Co-operation and Development (OCDE), patent data can be used as a source of information in order to measure science and technology activities. Thereby, this paper presents an analysis based on patent documents related to nanotechnology in the pharmaceutical sector. As a result, the analysis of patents demonstrate primarily that nanobiotechnology attracts high levels of R&D investments, including nanoparticle-based chemotherapeutic agents/drugs, monoclonal antibody nanoparticle complexes and their role in drug delivery or contrast agents with non-toxic effects.
Keywords: health; patents; nanotechnology; pharmaceutical

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Antunes, A.; Fierro, I.; Guerrante, R.; Mendes, F.; Alencar, M.S.M. Trends in Nanopharmaceutical Patents. Int. J. Mol. Sci. 2013, 14, 7016-7031.

AMA Style

Antunes A, Fierro I, Guerrante R, Mendes F, Alencar MSM. Trends in Nanopharmaceutical Patents. International Journal of Molecular Sciences. 2013; 14(4):7016-7031.

Chicago/Turabian Style

Antunes, Adelaide; Fierro, Iolanda; Guerrante, Rafaela; Mendes, Flavia; Alencar, Maria S.M. 2013. "Trends in Nanopharmaceutical Patents." Int. J. Mol. Sci. 14, no. 4: 7016-7031.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert